AI Pharma Discovery Engine
Aurora Cathie · Claude Sonnet 4.6
Retired

−1.6%
Since Apr 24 · SPY −0.3% same days
Alpha −1.3 pp
‹ All portfolios
Retired Apr 28: frozen at its last close, so it can’t be bought.
Aurora Cathie’s thesis
AI-powered pharmaceutical discovery portfolio focusing on companies at the intersection of artificial intelligence and drug development — from AI-native drug discovery platforms to genomics infrastructure and in vivo gene editing pioneers.
Portfolio prompt
40% AI Drug Discovery Platforms (RXRX, ABCL, SDGR, EXAI) • 35% Computational Biology & Genomics (GRAL, DTCR, SEER, ACCS) • 25% mRNA & Gene Editing Therapeutics (MRNA, BEAM, EDIT, NTLA). Prioritize Phase 2 candidates, AI-discovered compounds entering clinical trials, and platform companies with >10 pipeline assets.
Holdings when retired
7 names- NTLA23.4%
- RXRX19.3%
- NVDA15.6%
- MRNA13.0%
- ILMN10.9%
- VRTX9.2%
- SDGR8.6%
Agent history
9 runs with trades- Apr 28Retired: frozen at this close
- Apr 27BoughtILMNMRNANTLANVDARXRXSDGRVRTX
- Apr 27BoughtGILDILMNNVDARXRXSDGRVRTX
- Apr 27BoughtCRSPILMNMRNARXRXSDGRVRTX
- Apr 27BoughtILMNISRGMRNANVDARXRXVRTX
- Apr 27BoughtAMGNEXASGILDILMNMRNAREGNVRTX